Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Heidelberg Pharma AG's 3-Year ROIIC % for the quarter that ended in Nov. 2025 was 152.03%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Heidelberg Pharma AG's 3-Year ROIIC % or its related term are showing as below:
XTER:HPHA's 3-Year ROIIC % is ranked better than 81.89% of 1320
companies
in the Biotechnology industry
Industry Median: -4.82
vs XTER:HPHA: 152.03
Heidelberg Pharma AG (XTER:HPHA) 3-Year ROIIC % Explanation
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Heidelberg Pharma AG 3-Year ROIIC % Related Terms
Heidelberg Pharma AG 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Heidelberg Pharma AG's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:HPHA vs VRTX, REGN, RVMD: 3-Year ROIIC % Comparison
For the Biotechnology subindustry, Heidelberg Pharma AG's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Heidelberg Pharma AG 3-Year ROIIC % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Heidelberg Pharma AG's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Heidelberg Pharma AG's 3-Year ROIIC % falls into.
Heidelberg Pharma AG's 3-Year ROIIC % for the quarter that ended in Nov. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -47.045 (Nov. 2025) - -18.404 (Nov. 2022) )
/
( 15.752 (Nov. 2025) - 34.591 (Nov. 2022) )
=
-28.641
/
-18.839
=
152.03%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Heidelberg Pharma AG (XTER:HPHA) has a 3-Year ROIIC % of 152.03 as of Nov. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Heidelberg Pharma AG and its competitors. According to the industry distribution chart, Heidelberg Pharma AG ranks #239 out of 1320 companies in the Biotechnology industry, placing it in the top 18.1%.
Is Heidelberg Pharma AG's 3-Year ROIIC % too high?
Heidelberg Pharma AG's current 3-Year ROIIC % is 152.03. Based on the distribution chart, Heidelberg Pharma AG ranks #239 out of 1320 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Heidelberg Pharma AG has a GF Score™ of 51/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Heidelberg Pharma AG's 3-Year ROIIC % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Heidelberg Pharma AG ranks #239 out of 1320 companies for 3-Year ROIIC %. This places Heidelberg Pharma AG in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Biotechnology company?
A good 3-Year ROIIC % depends on the Biotechnology industry context. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Heidelberg Pharma AG and its competitors. Heidelberg Pharma AG's current 3-Year ROIIC % is 152.03. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Heidelberg Pharma AG stock overvalued right now?
Based on GuruFocus' analysis, Heidelberg Pharma AG (XTER:HPHA) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.94, compared to a current price of €2.60 — trading 11.6% below its estimated fair value. The current 3-Year ROIIC % is 152.03. Heidelberg Pharma AG's overall GF Score™ is 51/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Heidelberg Pharma AG (XTER:HPHA), the current 3-Year ROIIC % is 152.03 as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Heidelberg Pharma AG (XTER:HPHA) Overvalued in 2026?
Based on GuruFocus' analysis, Heidelberg Pharma AG stock appears to be undervalued.
The current stock price of €2.60 is trading 11.6% below its estimated GF Value™ of €2.94.
GuruFocus considers Heidelberg Pharma AG to be Modestly Undervalued.
Key valuation signals for XTER:HPHA:
3-Year ROIIC %: 152.03
GF Value™: €2.94 vs. price of €2.60 (11.6% below fair value)
No single metric tells the full story. See the XTER:HPHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Heidelberg Pharma AG is a biopharmaceutical company developing oncology treatments through antibody drug conjugates (ADCs), which combine antibody specificity with toxin potency to selectively target and kill cancer cells. The Company researches, develops, and produces these ADCs, and has built an ADC toolbox using various antibodies and payloads to address multiple cancers and overcome tumor resistance. Its activities focus on its proprietary ATAC technology based on Amanitin, the toxin of the death cap mushroom, leveraging its biological mechanism as a novel cancer therapy. The ATAC platform is used to develop proprietary ADC candidates and is also applied in collaborations with third parties.
51GF Score
Get the complete analysis for XTER:HPHA
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:HPHA has been successfully added to your 
